551 related articles for article (PubMed ID: 25817916)
1. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Min KS; Park K; Park JK
Eur Urol; 2011 Aug; 60(2):380-7. PubMed ID: 21458153
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
Munk NE; Knudsen JS; Comerma-Steffensen S; Simonsen U
Sex Med Rev; 2019 Jul; 7(3):430-441. PubMed ID: 30711478
[TBL] [Abstract][Full Text] [Related]
5. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
[TBL] [Abstract][Full Text] [Related]
6. PDE5 inhibitors: considerations for preference and long-term adherence.
Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
[TBL] [Abstract][Full Text] [Related]
7. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.
Porst H; Gacci M; Büttner H; Henneges C; Boess F
Eur Urol; 2014 Feb; 65(2):455-64. PubMed ID: 24119319
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of phosphodiesterase type 5 inhibitors for erectile dysfunction in diabetic men: a Bayesian network meta-analysis of randomized controlled trials.
Liao X; Qiu S; Bao Y; Wang W; Yang L; Wei Q
World J Urol; 2019 Jun; 37(6):1061-1074. PubMed ID: 30523399
[TBL] [Abstract][Full Text] [Related]
9. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of phosphodiesterase-5 inhibitors for treating erectile dysfunction in kidney transplant recipients: a meta-analysis.
Fanbin L; Mei Y; Yan Z; Yirong Y; Shaoling Z; Yong C; Peng X
Exp Clin Transplant; 2014 Jun; 12(3):184-9. PubMed ID: 24907716
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis.
Madeira CR; Tonin FS; Fachi MM; Borba HH; Ferreira VL; Leonart LP; Bonetti AF; Moritz RP; Trindade ACLB; Gonçalves AG; Fernandez-Llimos F; Pontarolo R
World J Urol; 2021 Mar; 39(3):953-962. PubMed ID: 32388784
[TBL] [Abstract][Full Text] [Related]
12. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Tadalafil Once-a-Day versus Tadalafil On-Demand in Patients with Erectile Dysfunction: A Systematic Review and Meta-Analyses.
Peng Z; Yang L; Dong Q; Wei Q; Liu L; Yang B
Urol Int; 2017; 99(3):343-352. PubMed ID: 28628914
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations.
Lombardo R; Tema G; De Nunzio C
Curr Drug Targets; 2021; 22(1):31-37. PubMed ID: 32981502
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.
Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Moon KH; Chung WS; Min KS; Suh JK; Hyun JS; Park K; Park JK
BJU Int; 2012 Dec; 110(11):1801-6. PubMed ID: 22448738
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study.
Ortaç M; Çayan S; Çalişkan MK; Yaman MÖ; Okutucu TM; Semerci MB; Altay AB; Balbay MD; Özcan MF; Kadioğlu A
Andrology; 2013 Jul; 1(4):549-55. PubMed ID: 23785019
[TBL] [Abstract][Full Text] [Related]
17. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis.
Limoncin E; Gravina GL; Corona G; Maggi M; Ciocca G; Lenzi A; Jannini EA
Andrology; 2017 Sep; 5(5):863-872. PubMed ID: 28787547
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial.
Park HJ; Park JK; Park K; Min K; Park NC
J Sex Med; 2010 Jun; 7(6):2209-2216. PubMed ID: 20412426
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
Berner MM; Kriston L; Harms A
Int J Impot Res; 2006; 18(3):229-35. PubMed ID: 16239897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
